Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
PF-06263726 · 1 trial · 1 indication
Changes from baseline on Draize toxicity assessment score.
Quantitative changes in ECG intervals.
| Arm | Type | Description |
|---|---|---|
| Cohort 1 Experimental Arm | EXPERIMENTAL | - |
| Cohort 2 Experimental Arm | EXPERIMENTAL | - |
| Cohort 3 Experimental Arm | EXPERIMENTAL | - |
| Cohort 3 Placebo Arm | PLACEBO_COMPARATOR | - |
| Cohort 4 Experimental Arm | EXPERIMENTAL | - |
| Cohort 4 Placebo Arm | PLACEBO_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| PF-06263726 | DRUG | Subjects will receive dose strength of 2% PF-06263276 (1.14 mg) and matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to two separate contralateral 20 cm2 areas on the back. |
| Placebo | DRUG | Subjects will receive dose strength of 2% PF-06263276 (11.4 mg) matching placebo in topical formulation (2.5 µL/cm2) to be applied twice daily to a 200 cm2 area on the back. |
Inclusion Criteria: * Healthy male and/or female subjects of non-childbearing potential between the ages of 18 and 55 years, inclusive. Healthy is defined as no clinically relevant abnormalities identified by a detailed medical history, full physical examination, including blood pressure and pulse ...
PF-06263726 is an investigational small molecule being developed by Pfizer, Inc. (PFE). It is currently in Phase 1 clinical development. The drug has been studied in healthy volunteers, and its therapeutic area is classified as Other.
PF-06263726 is being studied for use in healthy subjects. The completed Phase 1 trial evaluated tolerability, safety, and pharmacokinetics of the topical formulation in healthy volunteers. It is not approved for any disease or condition.
The molecular target of PF-06263726 has not been disclosed. The available information does not specify a target or target class for this investigational small molecule.
PF-06263726 is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker PFE. The drug is currently in Phase 1 clinical development.
PF-06263726 is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed.
PF-06263726 has one completed clinical trial, NCT01981681, a Phase 1 study in healthy subjects. The trial evaluated tolerability, safety, and pharmacokinetics of topical PF-06263276, enrolled 47 participants, and was conducted in Belgium.